Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Target Recruit Count
- 30
- Registration Number
- NCT06474481
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT06428019
- Locations
- 🇺🇸
Springfield Clinic /ID# 270145, Springfield, Illinois, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute /ID# 267643, Tulsa, Oklahoma, United States
🇫🇷Centre Hospitalier de la Côte Basque /ID# 266847, Bayonne, Pyrenees-Atlantiques, France
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Inhye Ahn
- Target Recruit Count
- 60
- Registration Number
- NCT06333262
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT06295770
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06291220
- Locations
- 🇦🇺
Royal Perth Hospital /ID# 256464, Perth, Western Australia, Australia
🇺🇸City of Hope /ID# 253904, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center /ID# 267158, Irvine, California, United States
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06265220
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸University of California, San Diego, San Diego, California, United States
Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- C. Babis Andreadis
- Target Recruit Count
- 30
- Registration Number
- NCT06252675
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06213311
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06192888
- Locations
- 🇺🇸
Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸Mayo Clinic (Data Collection Only), Rochester, Minnesota, United States
🇺🇸Washington University (Data Collection Only), Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.